TLR4 and respiratory tract infectious disorder: Oxidized phospholipids inhibitors were reported to ameliorate CS in humanized animal models of respiratory infections by decreasing the release of cytokines/macrophages in pulmonary tissue via the Toll-like receptor 4 (TLR4) and simultaneously causing induction of INF-γ signaling pathway [53].